Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).
The Program Committee of the AUA has accepted the Theralase®'s abstract titled: ' Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive ...
TipRanks on MSN3d
Theralase’s Innovative Bladder Cancer Treatment to be Highlighted at AUA Annual MeetingTheralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...
TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...
Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...
Protecting and conserving our natural heritage, predicting weather and environmental conditions, preventing and managing pollution, promoting clean growth and a sustainable environment for present and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback